Retrospective study shows CAR-T expansion and PD1 expression predict survival in DLBCL, suggesting new prognostic markers.
Key Points
To assess the relationship between CAR-T cell expansion dynamics, PD1 expression, and clinical outcomes in DLBCL patients treated with axicabtagene ciloleucel.
Conducted a retrospective study on adult DLBCL patients receiving axi-cel as third-line therapy.
Collected peripheral blood samples post-infusion and analyzed using flow cytometry on specified days.
Evaluated progression-free survival and overall survival with Kaplan-Meier estimates.
2-year progression-free survival was 39.6% and overall survival was 47.8%.
Higher CAR-T cell expansion correlated with improved survival outcomes.
Significant relationship found between PD1hi expression and lower disease progression rate.